Finance entity
Every one of those 1 sits in a single category, earnings. Raj Pruthi is most often covered alongside NeurAxis, Inc., which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 3 original sources each against 2.5 for the same window.
Last mentioned: Mar 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, earnings. Raj Pruthi is most often covered alongside NeurAxis, Inc., which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 3 original sources each against 2.5 for the same window. Their average consequence score of 5 runs below the beat's 6.5 for that window. Raj Pruthi appears in 1 tracked Finance story from March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 72 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Raj Pruthi. Shared-story counts are live from our verified record — not editorial picks.
Relmada Therapeutics and NeurAxis reported Q4 2025 results, highlighting critical pivots in clinical development and commercial execution. Relmada remains focused on its Phase 3 REL-1017 program for depression, while NeurAxis reports steady growth in its neuromodulation therapy for pediatric patients.
Raj Pruthi is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
